Charles H Hood Foundation

EIN 04-3507847 • Manchesterbythesea, MA

29 Old Neck RoadManchesterbythesea, MA 01944

Siviq Scores

Precomputed percentiles relative to similar nonprofits. These scores are descriptive rather than judgmental.

0.00x

Tied with the lowest-debt nonprofits in its peer group.

$100M-$250M nonprofits • Source year 2024

0.00x

Tied with the lowest-debt nonprofits in its peer group.

$100M-$250M nonprofits • Source year 2024

89%

Higher net margin than 97% of similar nonprofits.

$100M-$250M nonprofits • Source year 2024

Higher top officer pay than 12% of similar nonprofits.

Top officer pay equals 0.0% of source-year revenue.

$100M-$250M nonprofits • Source year 2024

40%

Faster asset growth than 95% of similar nonprofits.

$100M-$250M nonprofits • Annualized from 2023 to 2024

744%

Faster revenue growth than 98% of similar nonprofits.

$100M-$250M nonprofits • Annualized from 2023 to 2024

Balance Sheet

Liabilities / Assets9th percentile

Assets

$101,037,612

Up $29,029,462 (+40%) from 2023

Liabilities

Flat

Flat from 2023

Net Assets

$101,037,612

Up $29,029,462 (+40%) from 2023

Operations

Liabilities / Revenue10th percentile Net Margin97th percentile

Revenue

$28,190,532

Up $24,851,421 (+744%) from 2023

Expenses

$3,159,061

Up $461,803 (+17%) from 2023

Net Income

$25,031,471

Up $24,389,618 (+3800%) from 2023

Trend Graphs

Balance Sheet Trend

Asset Growth95th percentile

Grouped bars show assets, liabilities, and net assets across loaded filings.

Highlighted filing

2024

Assets$101,037,612

Liabilities$0

Net Assets$101,037,612

Open 2024 Filing

Operations Trend

Revenue Growth98th percentile

Revenue, expenses, and net income by year, with the latest filing highlighted.

Highlighted filing

2024

Revenue$28,190,532

Expenses$3,159,061

Net Income$25,031,471

Open 2024 Filing

Filings

Most recent year

2024 • Form 990PFDetailed filing. Detailed filing data is available for this year.

Open filing

Assets: $101,037,612
Liabilities: $0
Net assets: $101,037,612
Revenue: $28,190,532
Expenses: $3,159,061
Net income: $25,031,471

	Balance Sheet			Operations
Year	Assets	Liabilities	Net Assets	Revenue	Expenses	Net Income
2024Detailed filing. Detailed filing data is available for this year.	$101	$0.00	$101	$28.2	$3.16	$25.0
2023Detailed filing. Detailed filing data is available for this year.	$72.0	$0.00	$72.0	$3.34	$2.70	$0.64
2022Detailed filing. Detailed filing data is available for this year.	$66.7	$0.00	$66.7	$3.02	$3.33	$0.31
2021Detailed filing. Detailed filing data is available for this year.	$79.0	$0.00	$79.0	$6.70	$2.89	$3.80
2020Detailed filing. Detailed filing data is available for this year.	$73.5	$0.00	$73.5	$2.34	$2.46	$0.12
2019Detailed filing. Detailed filing data is available for this year.	$66.8	$0.00	$66.8	$1.99	$2.60	$0.61
2018Detailed filing. Detailed filing data is available for this year.	$58.8	$0.00	$58.8	$15.9	$3.52	$12.4
2017Detailed filing. Detailed filing data is available for this year.	$66.6	$0.00	$66.6	$4.32	$3.03	$1.29
2016Detailed filing. Detailed filing data is available for this year.	$59.4	$0.00	$59.4	$2.83	$3.22	$0.39
2015Summary only. Only limited summary data is available for this year.	$47.3	$0.00		$4.46	$3.21	$1.25
2014Summary only. Only limited summary data is available for this year.	$45.4	$0.00		$4.70	$3.09	$1.61
2013Summary only. Only limited summary data is available for this year.	$43.7	$0.00		$3.28	$2.85	$0.43
2012Summary only. Only limited summary data is available for this year.	$43.7	$0.00		$2.77	$2.86	$0.09
2011Summary only. Only limited summary data is available for this year.	$43.7	$0.00		$1.93	$2.67	$0.74

Latest Filing Detail

Jump To

Filing Snapshot

Filing Period: Jan 1, 2024 to Dec 31, 2024
Signed: Nov 11, 2025
Return Version: 2024v5.2

Compensation and Service Providers

Top Officer Pay12th percentile

Employees

Name	Title	Full / Part Time	Base	Other	Total
NEIL SMILEY	President And Treasurer	-	$0	-	-
JOHN O PARKER JR	Vice President And Clerk	-	$0	-	-
ROBERT C BOUTWELL	Trustee	-	$0	-	-
BARBARA BULA	Trustee	-	$0	-	-
BRENDON BULA	Trustee	-	$0	-	-
ELIZABETH HOOD	Trustee	-	$0	-	-
CLAY SMILEY	Trustee	-	$0	-	-

Grants and Assistance

Foundation Grants and Related Investments

Type	Recipient	Purpose	Status	Location	Amount
Paid Grant	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	HOOD PEDIATRIC INNOVATION HUB	PC	BOSTON, MA, US	$400,000
Paid Grant	YALE UNIVERSITY	CHILD HEALTH RESEARCH AWARD - SUPPORTING REFUGEE MENTAL HEALTH THROUGH TRANSLATION OF EVALUATIVE INSTRUMENTS AND THROUGH A PREVENTIVE MENTAL HEALTH INTERVENTION	PC	NEW HAVEN, CT, US	$100,000
Paid Grant	MASSACHUSETTS GENERAL HOSPITAL	CHILD HEALTH RESEARCH AWARD - TACKLING PULMONARY HYPOPLASIA WITH GENETIC, EPIGENETIC AND STEM CELL APPROACHES.	PC	BOSTON, MA, US	$100,000
Paid Grant	BOSTON COLLEGE	CHILD HEALTH RESEARCH AWARD - IMPROVING CHILDHOOD TUBERCULOSIS TREATMENT OUTCOMES AND POST-TB LUNG FUNCTIONING AND QUALITY OF LIFE IN RURAL SOUTH AFRICA	PC	NEW YORK, NY, US	$100,000
Paid Grant	BOSTON CHILDREN'S HOSPITAL	CHILD HEALTH RESEARCH AWARD - IDENTIFYING EEG-BASED BIOMARKERS OF LANGUAGE GROWTH IN PRESCHOOL-AGED CHILDREN WITH DOWN SYNDROME	PC	BOSTON, MA, US	$100,000
Paid Grant	BOSTON CHILDREN'S HOSPITAL	CHILD HEALTH RESEARCH AWARD - CHARACTERIZING THE ROLE OF TWO SUBCORTICAL NUCLEI IN PREFRONTAL REGULATION OF ATTENTION	PC	BOSTON, MA, US	$100,000
Paid Grant	BOSTON CHILDREN'S HOSPITAL	CHILD HEALTH RESEARCH AWARD - POSTNATAL EXPOSURE TO HYPEROXIA CAUSES MALADAPTATION OF THE PREMATURE INTESTINE	PC	BOSTON, MA, US	$100,000
Paid Grant	BOSTON CHILDREN'S HOSPITAL	CHILD HEALTH RESEARCH AWARD - ROLE OF XENOBIOTIC PATHWAYS TO MODULATE INTESTINAL EPITHELIAL METABOLISM, AS POSSIBLE TARGETS FOR OBESITY AND DIABETES	PC	BOSTON, MA, US	$100,000
Paid Grant	BRIGHAM AND WOMEN'S HOSPITAL	CHILD HEALTH RESEARCH AWARD - THE ROLE OF MESENCHYMAL STEM CELLS TO ENHANCE IMMUNE FUNCTION IN A MODEL OF NEONATAL INFECTION	PC	BOSTON, MA, US	$100,000
Paid Grant	MASSACHUSETTS EYE AND EAR INFIRMARY	CHILD HEALTH RESEARCH AWARD - ADVANCING THE RETINOIC ACID SIGNALING ACTIVATOR AS A NOVEL THERAPEUTIC IN MOUSE MODELS OF RETINAL DEGENERATION	PC	BOSTON, MA, US	$100,000
Paid Grant	MASSACHUSETTS GENERAL HOSPITAL	CHILD HEALTH RESEARCH AWARD - DECIPHERING THE MECHANISM UNDERLYING SHORT- AND LONG-TERM AIRWAY HYPERRESPONSIVENESS FOLLOWING EARLY-LIFE RSV INFECTION	PC	BOSTON, MA, US	$100,000
Paid Grant	MASSACHUSETTS GENERAL HOSPITAL	CHILD HEALTH RESEARCH AWARD - EVALUATING EFFECTIVE COMBINATIONS OF MODIFIABLE FACTORS FOR PREVENTING YOUTH DEPRESSION RISK	PC	BOSTON, MA, US	$100,000
Paid Grant	HARVARD UNIVERSITY	CHILD HEALTH RESEARCH AWARD - TARGETING LIPID DYSREGULATION IN HEREDITARY SPASTIC PARAPLEGIA	PC	BOSTON, MA, US	$100,000
Paid Grant	YALE UNIVERSITY	CHILD HEALTH RESEARCH AWARD - IMPACT OF EARLY LIFE IMMUNE CHALLENGES ON BRAIN WIRING	PC	NEW HAVEN, CT, US	$100,000
Paid Grant	MASSACHUSETTS EYE AND EAR INFIRMARY	CHILD HEALTH RESEARCH AWARD - CHARACTERIZATION OF SENSORINEURAL HEARING LOSS IN NEUROFIBROMATOSIS TYPE 2	PC	BOSTON, MA, US	$100,000
Paid Grant	BOSTON CHILDREN'S HOSPITAL	CHILD HEALTH RESEARCH AWARD - NANOBODY-BASED IMMUNOTHERAPY FOR MODULATING INFLAMMATION IN JUVENILE IDIOPATHIC ARTHRITIS	PC	BOSTON, MA, US	$100,000
Paid Grant	DANA-FARBER CANCER INSTITUTE	CHILD HEALTH RESEARCH AWARD - TARGETING CHROMATIN REGULATORS IN NUP98-REARRANGED ACUTE MYELOID LEUKEMIA	PC	BOSTON, MA, US	$100,000
Paid Grant	HARVARD PILGRIM HEALTH CARE	CHILD HEALTH RESEARCH AWARD - SOCIOECONOMIC INEQUITIES IN RSV IMMUNIZATION AND POPULATION-BASED OUTCOMES	PC	BOSTON, MA, US	$100,000
Paid Grant	BOSTON CHILDREN'S HOSPITAL	CHILD HEALTH RESEARCH AWARD - UNDERSTANDING MECHANISMS FOR IMPROVED PEDIATRIC SKELETAL HEALTH: NOVEL REGULATORS OF CHONDROCYTE-TO-OSTEOBLAST TRANSDIFFERENTIATION	PC	BOSTON, MA, US	$100,000
Paid Grant	BOSTON UNIVERSITY	CHILD HEALTH RESEARCH AWARD - HISTONE MARKS PROFILING: DECODING CELLULAR MECHANISMS IN CONGENITAL RARE DISORDERS CAUSED BY PATHOGENIC VARIANTS IN CHROMATIN-MODIFIER GENES	PC	NEW YORK, NY, US	$100,000
Paid Grant	MASSACHUSETTS GENERAL HOSPITAL	CHILD HEALTH RESEARCH AWARD - EPIGENETIC REGULATION OF NEURAL EXCITABILITY IN A MOUSE MODEL OF INFANTILE EPILEPSY	PC	BOSTON, MA, US	$100,000
Paid Grant	DARTMOUTH-HITCHCOCK CLINIC	CHILD HEALTH RESEARCH AWARD - EVALUATING MECHANISMS OF ENVIRONMENTAL CHEMICAL EXPOSURE WITH DEVELOPING ZEBRAFISH URINARY SYSTEM	PC	LEBANON, NH, US	$70,000

Filing and Contact Details

Filer

Filer Name: Charles H Hood Foundation
EIN: 04-3507847
Phone: 6172792230
Address: 29 OLD NECK ROAD, MANCHESTERBYTHESEA, MA 01944

Signing Officer

Name: Neil Smiley
Title: President and Treasurer
Phone: 6172792230
Signed: 2025-11-11
Discuss with paid preparer: Yes

Preparer

Firm: Aafcpas Inc
Address: 50 WASHINGTON STREET, WESTBOROUGH, MA 01581
Preparer: Joyce Ripianzi CPA
Phone: 5083669100

Raw XML AppendixShowing 400 of 1,130 raw XML fields

This appendix keeps the raw XML leaves available for debugging and edge-case review. The human report above is the primary experience.

Path	#	Value
AccountingFeesSchedule/AccountingFeesDetail/Amt	0	29863
AccountingFeesSchedule/AccountingFeesDetail/CategoryTxt	0	ACCOUNTING & TAX PREPARATION FEES
AccountingFeesSchedule/AccountingFeesDetail/DisbursementsCharitablePrpsAmt	0	29863
AccountingFeesSchedule/AccountingFeesDetail/NetInvestmentIncomeAmt	0	0
AllOthProgRltdInvestmentsSch/AllOtherProgramRelatedInvstGrp/Amt	0	49995
AllOthProgRltdInvestmentsSch/AllOtherProgramRelatedInvstGrp/Amt	1	100000
AllOthProgRltdInvestmentsSch/AllOtherProgramRelatedInvstGrp/Desc	0	ARGUS COGNITIVE, INC. - LEBANON, NH SIMPLE AGREEMENT FOR FUTURE EQUITY
AllOthProgRltdInvestmentsSch/AllOtherProgramRelatedInvstGrp/Desc	1	MULBERRY THERAPEUTICS - WELLESLEY, MA CONVERTIBLE PROMISSORY NOTE
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/AnyDiversionByGranteeTxt	0	NONE, SEE BELOW
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/AnyDiversionByGranteeTxt	1	NONE, SEE BELOW
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/AnyDiversionByGranteeTxt	2	NONE, SEE BELOW
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/AnyDiversionByGranteeTxt	3	NONE, SEE BELOW
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/AnyDiversionByGranteeTxt	4	NONE, SEE BELOW
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/AnyDiversionByGranteeTxt	5	NONE, SEE BELOW
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/AnyDiversionByGranteeTxt	6	NONE, SEE BELOW
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/AnyDiversionByGranteeTxt	7	NONE, SEE BELOW
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/AnyDiversionByGranteeTxt	8	NONE, SEE BELOW
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/AnyDiversionByGranteeTxt	9	NONE, SEE BELOW
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/AnyDiversionByGranteeTxt	10	NONE, SEE BELOW
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/AnyDiversionByGranteeTxt	11	NONE, SEE BELOW
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/AnyDiversionByGranteeTxt	12	NONE, SEE BELOW
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/AnyDiversionByGranteeTxt	13	NONE, SEE BELOW
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/AnyDiversionByGranteeTxt	14	NONE, SEE BELOW
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/AnyDiversionByGranteeTxt	15	NONE, SEE BELOW
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/AnyDiversionByGranteeTxt	16	NONE, SEE BELOW
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/AnyDiversionByGranteeTxt	17	NONE, SEE BELOW
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/AnyDiversionByGranteeTxt	18	NONE, SEE BELOW
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/AnyDiversionByGranteeTxt	19	NONE, SEE BELOW
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/AnyDiversionByGranteeTxt	20	NONE, SEE BELOW
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/AnyDiversionByGranteeTxt	21	NONE, SEE BELOW
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/AnyDiversionByGranteeTxt	22	NONE, SEE BELOW
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/AnyDiversionByGranteeTxt	23	NONE, SEE BELOW
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/AnyDiversionByGranteeTxt	24	NONE, SEE BELOW
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/AnyDiversionByGranteeTxt	25	NONE, SEE BELOW
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/AnyDiversionByGranteeTxt	26	NONE, SEE BELOW
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/AnyDiversionByGranteeTxt	27	NONE, SEE BELOW
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/BusinessName/BusinessNameLine1Txt	0	ALDATU BIOSCIENCES INC
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/BusinessName/BusinessNameLine1Txt	1	ANIDA PHARMA INC
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/BusinessName/BusinessNameLine1Txt	2	ARGUS COGNITIVE INC
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/BusinessName/BusinessNameLine1Txt	3	ARGUS COGNITIVE INC
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/BusinessName/BusinessNameLine1Txt	4	ARGUS COGNITIVE INC
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/BusinessName/BusinessNameLine1Txt	5	BIOROSA TECHNOLOGIES INC
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/BusinessName/BusinessNameLine1Txt	6	BIOROSA TECHNOLOGIES INC
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/BusinessName/BusinessNameLine1Txt	7	BREEGI SCIENTIFIC INC
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/BusinessName/BusinessNameLine1Txt	8	DECK THERAPEUTICS INC
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/BusinessName/BusinessNameLine1Txt	9	INKSPACE IMAGING INC
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/BusinessName/BusinessNameLine1Txt	10	MESENTECH INC
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/BusinessName/BusinessNameLine1Txt	11	MOTHERS MILK IS BEST INC
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/BusinessName/BusinessNameLine1Txt	12	MULBERRY BIOTHERAPEUTICS INC
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/BusinessName/BusinessNameLine1Txt	13	MULBERRY BIOTHERAPEUTICS INC
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/BusinessName/BusinessNameLine1Txt	14	NEOPENDA PBC
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/BusinessName/BusinessNameLine1Txt	15	NICOLETTE INC
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/BusinessName/BusinessNameLine1Txt	16	NONINVASIX INC
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/BusinessName/BusinessNameLine1Txt	17	NONINVASIX INC
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/BusinessName/BusinessNameLine1Txt	18	NONINVASIX INC
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/BusinessName/BusinessNameLine1Txt	19	NOVONATE INC
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/BusinessName/BusinessNameLine1Txt	20	NURTURE GENOMICS
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/BusinessName/BusinessNameLine1Txt	21	PLAKOUS THERAPEUTICS
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/BusinessName/BusinessNameLine1Txt	22	PRAPELA LLC
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/BusinessName/BusinessNameLine1Txt	23	PRAPELA LLC
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/BusinessName/BusinessNameLine1Txt	24	SMOLTAP INC
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/BusinessName/BusinessNameLine1Txt	25	SMOLTAP INC
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/BusinessName/BusinessNameLine1Txt	26	STINGRAY THERAPEUTICS
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/BusinessName/BusinessNameLine1Txt	27	THINKMD INC
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/DatesOfReportsByGranteeTxt	0	PRI REPORTS - 6/12/2024, 6/27/2025
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/DatesOfReportsByGranteeTxt	1	PRI REPORTS - 6/24/2024, 1/3/2025, 6/17/2025
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/DatesOfReportsByGranteeTxt	2	PRI REPORTS - 3/5/2024,5/18/2024, 6/6/2024, 7/3/2024, 7/26/2024, 9/9/2024, 9
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/DatesOfReportsByGranteeTxt	3	PRI REPORTS - 3/5/2024,5/18/2024, 6/6/2024, 7/3/2024, 7/26/2024, 9/9/2024, 9
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/DatesOfReportsByGranteeTxt	4	PRI REPORTS - 3/5/2024,5/18/2024, 6/6/2024, 7/3/2024, 7/26/2024, 9/9/2024, 9
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/DatesOfReportsByGranteeTxt	5	PRI REPORTS - 1/8/2024, 9/24/2024, 9/3/2025
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/DatesOfReportsByGranteeTxt	6	PRI REPORTS - 1/8/2024, 9/24/2024, 9/3/2025
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/DatesOfReportsByGranteeTxt	7	PRI REPORTS - 6/3/2024, 10/1/2024, 9/26/2025
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/DatesOfReportsByGranteeTxt	8	PRI REPORTS - 6/26/2024, 2/4/2025, 7/4/2025
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/DatesOfReportsByGranteeTxt	9	PRI REPORTS - 8/12/2024, 7/2/2025, 9/8/2025
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/DatesOfReportsByGranteeTxt	10	PRI REPORTS - 6/4/2024, 6/5/2024, 11/19/2024, 3/6/2025, 5/20/2025
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/DatesOfReportsByGranteeTxt	11	PRI REPORT - 4/1/2025, 5/23/2025
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/DatesOfReportsByGranteeTxt	12	PRI REPORT - 6/11/2024, 12/16/2024, 6/19/2025
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/DatesOfReportsByGranteeTxt	13	PRI REPORT - 6/11/2024, 12/16/2024, 6/19/2025
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/DatesOfReportsByGranteeTxt	14	PRI REPORT - 2/7/2025, 9/8/2025
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/DatesOfReportsByGranteeTxt	15	PRI REPORT - 4/10/2024, 6/17/2024, 10/15/2025, 4/16/2025, 6/16/2025
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/DatesOfReportsByGranteeTxt	16	PRI REPORTS - 5/31/2024, 1/24/2025, 7/23/2025
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/DatesOfReportsByGranteeTxt	17	PRI REPORTS - 5/31/2024, 1/24/2025, 7/23/2025
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/DatesOfReportsByGranteeTxt	18	PRI REPORTS - 5/31/2024, 1/24/2025, 7/23/2025
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/DatesOfReportsByGranteeTxt	19	PRI REPORTS - 7/25/2023, 7/27/2023
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/DatesOfReportsByGranteeTxt	20	PRI REPORT - 6/23/2024, 7/25/2025, 8/12/2025
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/DatesOfReportsByGranteeTxt	21	PRI REPORTS - 2/2/2024, 6/6/2024, 5/20/2025
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/DatesOfReportsByGranteeTxt	22	PRI REPORTS - 6/17/2024, 9/24/2024, 2/1/2025, 4/1/2025, 9/4/2025
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/DatesOfReportsByGranteeTxt	23	PRI REPORTS - 6/17/2024, 9/24/2024, 2/1/2025, 4/1/2025, 9/4/2025
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/DatesOfReportsByGranteeTxt	24	PRI REPORTS - 5/30/2024, 9/3/2024, 4/23/2025, 5/9/2025, 5/28/2025
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/DatesOfReportsByGranteeTxt	25	PRI REPORTS - 5/30/2024, 9/3/2024, 4/23/2025, 5/9/2025, 5/28/2025
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/DatesOfReportsByGranteeTxt	26	PRI REPORTS - 3/6/2024, 4/11/2024, 6/12/2024, 1/5/2025, 6/26/2025
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/DatesOfReportsByGranteeTxt	27	PRI REPORTS - 2/1/2024, 6/4/2024, 10/14/2024, 3/31/2025, 5/28/2025
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ExpendedByGranteeAmt	0	100000
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ExpendedByGranteeAmt	1	250000
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ExpendedByGranteeAmt	2	250000
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ExpendedByGranteeAmt	3	25000
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ExpendedByGranteeAmt	4	49995
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ExpendedByGranteeAmt	5	150000
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ExpendedByGranteeAmt	6	100000
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ExpendedByGranteeAmt	7	250000
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ExpendedByGranteeAmt	8	200000
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ExpendedByGranteeAmt	9	250000
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ExpendedByGranteeAmt	10	250000
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ExpendedByGranteeAmt	11	0
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ExpendedByGranteeAmt	12	222101
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ExpendedByGranteeAmt	13	0
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ExpendedByGranteeAmt	14	172110
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ExpendedByGranteeAmt	15	200000
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ExpendedByGranteeAmt	16	150000
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ExpendedByGranteeAmt	17	150000
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ExpendedByGranteeAmt	18	7000
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ExpendedByGranteeAmt	19	150000
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ExpendedByGranteeAmt	20	250000
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ExpendedByGranteeAmt	21	250000
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ExpendedByGranteeAmt	22	250000
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ExpendedByGranteeAmt	23	42700
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ExpendedByGranteeAmt	24	99997
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ExpendedByGranteeAmt	25	100000
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ExpendedByGranteeAmt	26	250000
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ExpendedByGranteeAmt	27	150000
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ForeignAddress/AddressLine1Txt	0	2222 HEALTH SCIENCES RD
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ForeignAddress/CityNm	0	VANCOUVER
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ForeignAddress/CountryCd	0	CA
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ForeignAddress/ForeignPostalCd	0	V6T2B9
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ForeignAddress/ProvinceOrStateNm	0	BRITISH COLUMBIA
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantAmt	0	100000
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantAmt	1	250000
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantAmt	2	250000
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantAmt	3	25000
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantAmt	4	49995
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantAmt	5	150000
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantAmt	6	100000
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantAmt	7	250000
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantAmt	8	200000
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantAmt	9	250000
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantAmt	10	250000
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantAmt	11	200000
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantAmt	12	250000
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantAmt	13	100000
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantAmt	14	200000
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantAmt	15	200000
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantAmt	16	150000
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantAmt	17	150000
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantAmt	18	7000
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantAmt	19	150000
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantAmt	20	250000
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantAmt	21	250000
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantAmt	22	250000
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantAmt	23	50000
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantAmt	24	99997
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantAmt	25	100000
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantAmt	26	250000
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantAmt	27	150000
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantDt	0	2016-02-23
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantDt	1	2020-12-21
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantDt	2	2021-05-10
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantDt	3	2023-07-10
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantDt	4	2024-06-24
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantDt	5	2020-07-15
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantDt	6	2022-11-15
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantDt	7	2017-06-26
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantDt	8	2022-10-12
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantDt	9	2022-10-20
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantDt	10	2020-11-02
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantDt	11	2024-12-27
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantDt	12	2023-12-26
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantDt	13	2024-12-20
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantDt	14	2024-11-15
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantDt	15	2021-12-23
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantDt	16	2015-12-30
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantDt	17	2016-07-27
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantDt	18	2017-07-27
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantDt	19	2022-08-03
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantDt	20	2023-12-26
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantDt	21	2023-07-03
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantDt	22	2018-07-02
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantDt	23	2023-12-20
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantDt	24	2022-07-25
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantDt	25	2023-09-11
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantDt	26	2019-04-08
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/GrantDt	27	2018-05-17
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/PurposeOfGrantTxt	0	TO SUPPORT THE USE AND DEVELOPMENT OF A SIMPLE, RAPID, THERMOSTABLE KIT THAT IDENTIFIES CLINICALLY ACTIONABLE HIV MUTATIONS FOUND IN PATIENTS FAILING A FIRST-LINE DRUG REGIMEN, THEREBY SUPPORTING THE ADVANCEMENT OF SCIENCE AND RELIEF OF THE POOR, DISTRESSED AND UNDERPRIVILEGED.
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/PurposeOfGrantTxt	1	TO SUPPORT THE PRECLINICAL DEVELOPMENT OF A PREVENTATIVE TREATMENT FOR RETINOPATHY OF PREMATURITY, THEREBY SUPPORTING THE ADVANCEMENT OF SCIENCE AND RELIEF OF THE POOR, DISTRESSED AND UNDERPRIVILEGED.
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/PurposeOfGrantTxt	2	TO SUPPORT THE DEVELOPMENT AND CLINICAL TESTING OF THE CORPORATION'S CLINICAL DECISION SUPPORT SOFTWARE FOR USE IN PEDIATRIC INDICATIONS, INCLUDING AUTISM AND PEDIATRIC CARDIOLOGY, THEREBY SUPPORTING RELIEF OF THE POOR, DISTRESSED AND UNDERPRIVILEGED AND LESSENING THE BURDEN OF THE GOVERNMENT.
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/PurposeOfGrantTxt	3	TO SUPPORT THE DEVELOPMENT AND CLINICAL TESTING OF THE CORPORATION'S CLINICAL DECISION SUPPORT SOFTWARE FOR USE IN PEDIATRIC INDICATIONS, INCLUDING AUTISM AND PEDIATRIC CARDIOLOGY, THEREBY SUPPORTING RELIEF OF THE POOR, DISTRESSED AND UNDERPRIVILEGED AND LESSENING THE BURDEN OF THE GOVERNMENT.
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/PurposeOfGrantTxt	4	TO SUPPORT THE DEVELOPMENT AND CLINICAL TESTING OF THE CORPORATION'S CLINICAL DECISION SUPPORT SOFTWARE FOR USE IN PEDIATRIC INDICATIONS, INCLUDING AUTISM AND PEDIATRIC CARDIOLOGY, THEREBY SUPPORTING RELIEF OF THE POOR, DISTRESSED AND UNDERPRIVILEGED AND LESSENING THE BURDEN OF THE GOVERNMENT.
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/PurposeOfGrantTxt	5	TO SUPPORT THE DEVELOPMENT OF A BLOOD-BASED STANDARD-OF-CARE DIAGNOSTIC FOR AUTISM SPECTRUM DISORDERS ("ASD") THAT IS INTENDED TO LEAD TO EARLIER DETECTION OF ASD THAN IS CURRENTLY AVAILABLE, THEREBY SUPPORTING THE ADVANCEMENT OF SCIENCE AND LESSENING THE BURDEN OF THE GOVERNMENT.
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/PurposeOfGrantTxt	6	TO SUPPORT THE DEVELOPMENT OF A BLOOD-BASED STANDARD-OF-CARE DIAGNOSTIC FOR AUTISM SPECTRUM DISORDERS ("ASD") THAT IS INTENDED TO LEAD TO EARLIER DETECTION OF ASD THAN IS CURRENTLY AVAILABLE, THEREBY SUPPORTING THE ADVANCEMENT OF SCIENCE AND LESSENING THE BURDEN OF THE GOVERNMENT.
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/PurposeOfGrantTxt	7	THE FUNDS WILL BE USED TO CONDUCT A THOROUGH CLINICAL ASSESSMENT OF BSI'S NOVEL NEONATAL INTENSIVE CARE INCUBATOR "(NICI)" IN HONDURAS AND ZAMBIA AND TO AID THE COMMERCIALIZATION EFFORTS OF THIS LIFE-SAVING MEDICAL DEVICE, THEREBY LESSENING THE BURDEN OF THE GOVERNMENT AND RELIEF OF THE POOR, DISTRESSED AND UNDERPRIVILEGED.
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/PurposeOfGrantTxt	8	TO SUPPORT THE DEVELOPMENT OF SEMI-SYNTHETIC OMEGA-3 COMPOUNDS THAT BLOCK MULTIPLE CELL-DEATH PATHWAYS INDUCED BY HYPOXIC-ISCHEMIC INJURY IN NEONATES.
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/PurposeOfGrantTxt	9	TO SUPPORT THE DEVELOPMENT OF FLEXIBLE, LIGHTWEIGHT, LOW COST MRI COILS DESIGNED SPECIFICALLY FOR PEDIATRIC PATIENTS, WHILE ALSO IMPROVING IMAGE RESOLUTION AND REDUCING MRI FAILURE RATES.
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/PurposeOfGrantTxt	10	TO SUPPORT THE ADVANCEMENT OF SCIENCE AND PROMOTION OF HEALTH THROUGH THE PRECLINICAL RESEARCH OF ANABOLIC BONE THERAPEUTICS THAT CAN INCREASE BONE MASS TO STRENGTHEN THE SKELETON AND THE DEVELOPMENT OF A DRUG DELIVERY SYSTEM TO BE INITIALLY APPLIED TO TWO PEDIATRIC RARE DISEASES: OSTEOGENESIS IMPERFECTA AND DUCHENNE MUSCULAR DYSTROPHY.
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/PurposeOfGrantTxt	11	TO SUPPORT THE CONDUCTING OF SCIENTIFIC RESEARCH RELATED TO THE DEVELOPMENT OF A MEDICAL DEVICE THAT CONCENTRATES HUMAN MILK TO PROVIDE LOW VOLUME, HIGH NUTRIENT FEEDINGS PRESCRIBED FOR PRETERM INFANTS.
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/PurposeOfGrantTxt	12	TO SUPPORT PRECLINICAL WORK RELATING TO THE DEVELOPMENT OF A BACTERIA-MEDIATED THERAPY FOR NEUROFIBROMATOSIS TYPE 2.
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/PurposeOfGrantTxt	13	TO SUPPORT PRECLINICAL WORK RELATING TO THE DEVELOPMENT OF A BACTERIA-MEDIATED THERAPY FOR NEUROFIBROMATOSIS TYPE 2.
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/PurposeOfGrantTxt	14	TO SUPPORT THE CONDUCTING OF SCIENTIFIC RESEARCH IN THE PUBLIC INTEREST RELATED TO THE DEVELOPMENT OF AFFORDABLE, LIFE-SAVING MEDICAL DEVICES TAILORED FOR LOW-RESOURCE SETTINGS SUCH AS KENYA AND EAST AFRICA.
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/PurposeOfGrantTxt	15	TO DEVELOP AND TEST A TABLET-BASED APPLICATION THAT TRANSLATES DATA PULLED FROM A BABY'S ELECTRONIC MEDICAL RECORD INTO EASILY UNDERSTOOD, SIMPLE SENTENCES COMPLEMENTED BY VISUAL AIDS, SUCH AS GRAPHS AND CHARTS, FOR THE BENEFIT OF THE PUBLIC, INCLUDING PARENTS, IN AN ATTEMPT TO CHANGE THE STANDARD OF CARE BY IMPROVING LIVES, REDUCING MEDICAL ERRORS, AND REDUCING OVERALL HEALTHCARE COSTS.
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/PurposeOfGrantTxt	16	TO SUPPORT THE USE AND DEVELOPMENT OF THE COMPANY'S PEDIATRIC BRAIN OXYGENATION MONITORING SYSTEM, WHICH HAS THE POTENTIAL TO MORE ACCURATELY ASSESS THE RISK OF BRAIN HYPOXIA IN FETUSES AND NEONATES, THEREBY SUPPORTING THE ADVANCEMENT OF SCIENCE AND LESSENING THE BURDEN OF THE GOVERNMENT.
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/PurposeOfGrantTxt	17	TO SUPPORT THE USE AND DEVELOPMENT OF THE COMPANY'S PEDIATRIC BRAIN OXYGENATION MONITORING SYSTEM, WHICH HAS THE POTENTIAL TO MORE ACCURATELY ASSESS THE RISK OF BRAIN HYPOXIA IN FETUSES AND NEONATES, THEREBY SUPPORTING THE ADVANCEMENT OF SCIENCE AND LESSENING THE BURDEN OF THE GOVERNMENT.
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/PurposeOfGrantTxt	18	TO SUPPORT THE USE AND DEVELOPMENT OF THE COMPANY'S PEDIATRIC BRAIN OXYGENATION MONITORING SYSTEM, WHICH HAS THE POTENTIAL TO MORE ACCURATELY ASSESS THE RISK OF BRAIN HYPOXIA IN FETUSES AND NEONATES, THEREBY SUPPORTING THE ADVANCEMENT OF SCIENCE AND LESSENING THE BURDEN OF THE GOVERNMENT.
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/PurposeOfGrantTxt	19	TO SUPPORT THE PERFORMANCE OF SCIENTIFIC RESEARCH TO BENEFIT THE PUBLIC BY DEVELOPING MEDICAL DEVICES FOR PATIENTS IN THE NEONATAL INTENSIVE CARE UNIT.
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/PurposeOfGrantTxt	20	TO SUPPORT THE PRE-COMMERCIAL AND PILOT DEVELOPMENT OF A SCREENING AND TELEHEALTH PLATFORM TO PROVIDE GENETIC INSIGHTS THAT HELP PARENTS AND THEIR MEDICAL PROVIDERS BETTER UNDERSTAND RISKS FROM CHILDBIRTH INTO ADOLESCENCE.
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/PurposeOfGrantTxt	21	TO SUPPORT THE PRECLINICAL DEVELOPMENT OF A BIOLOGIC TO TREAT BABIES DIAGNOSED OR AT RISK OF DEVELOPING NECROTIZING ENTEROCOLITIS (NEC).
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/PurposeOfGrantTxt	22	TO SUPPORT THE DEVELOPMENT OF THE COMPANY'S SLEEP TECHNOLOGY PRODUCTS FOR IMPROVING THE HEALTH OF INFANTS WHO COULD BENEFIT FROM WITHDRAWAL TREATMENT AND POST-WITHDRAWAL SUPPORT OF NEONATAL ABSTINENCE SYNDROME ("NAS") A CONDITION CAUSED BY THE PRENATAL USE OF OPIOIDS OR OTHER DRUGS BY PREGNANT WOMEN, THEREBY SUPPORTING THE ADVANCEMENT OF SCIENCE, LESSENING THE BURDEN OF THE GOVERNMENT, AND RELIEF OF THE POOR, DISTRESSED AND UNDERPRIVILEGED.
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/PurposeOfGrantTxt	23	TO SUPPORT THE DEVELOPMENT OF THE COMPANY'S SLEEP TECHNOLOGY PRODUCTS FOR IMPROVING THE HEALTH OF INFANTS WHO COULD BENEFIT FROM WITHDRAWAL TREATMENT AND POST-WITHDRAWAL SUPPORT OF NEONATAL ABSTINENCE SYNDROME ("NAS") A CONDITION CAUSED BY THE PRENATAL USE OF OPIOIDS OR OTHER DRUGS BY PREGNANT WOMEN, THEREBY SUPPORTING THE ADVANCEMENT OF SCIENCE, LESSENING THE BURDEN OF THE GOVERNMENT, AND RELIEF OF THE POOR, DISTRESSED AND UNDERPRIVILEGED.
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/PurposeOfGrantTxt	24	TO SUPPORT THE PERFORMANCE OF SCIENTIFIC RESEARCH TO DEVELOP A NOVEL DEVICE WHICH HOLDS AN INFANT STABLE DURING THE LUMBER PUNCTURE PROCEDURE WHEN ADMINISTERING A SPINAL TAP TO DIAGNOSE MENINGITIS IN IN FEBRILE INFANTS UP TO FOUR WEEKS OLD.
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/PurposeOfGrantTxt	25	TO SUPPORT THE PERFORMANCE OF SCIENTIFIC RESEARCH TO DEVELOP A NOVEL DEVICE WHICH HOLDS AN INFANT STABLE DURING THE LUMBER PUNCTURE PROCEDURE WHEN ADMINISTERING A SPINAL TAP TO DIAGNOSE MENINGITIS IN IN FEBRILE INFANTS UP TO FOUR WEEKS OLD.
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/PurposeOfGrantTxt	26	FUNDS WILL BE USED FOR PRECLINICAL WORK FOCUSED ON PEDIATRIC BRAIN CANCERS, INCLUDING WORK TO DEVELOP PRECLINICAL MODELS AND TO TEST COMPOUNDS AGAINST MEDULLOBLASTOMA, AN ULTRA-RARE PEDIATRIC BRAIN CANCER, THEREBY SUPPORTING THE ADVANCEMENT OF SCIENCE.
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/PurposeOfGrantTxt	27	FOR DEVELOPING INTEGRATED CLINICAL ASSESSMENT AND DATA ANALYTICS PLATFORMS AND OTHER DERIVATIVE PRODUCTS THAT TRANSFORM POINT-OF-CARE MEDICINE BY PUTTING VALIDATED CLINICAL ASSESSMENT CAPABILITY AND INCREASED HEALTHCARE KNOWLEDGE INTO THE HANDS OF CLINICALLY UNTRAINED HEALTHCARE PROFESSIONALS AND FAMILIES THEREBY LESSENING THE BURDEN OF THE GOVERNMENT, AND RELIEF OF THE POOR, DISTRESSED AND UNDERPRIVILEGED.
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ResultsOfVerificationTxt	0	THE TRUSTEES MEET WITH ALDATU BIOSCIENCES, INC. MANAGEMENT ON A REGULAR BASIS AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY.
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ResultsOfVerificationTxt	1	THE TRUSTEES MEET WITH ANIDA PHARMA, INC. MANAGEMENT ON A REGULAR BASIS, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ResultsOfVerificationTxt	2	THE TRUSTEES MEET WITH ARGUS COGNITIVE, INC. MANAGEMENT ON A REGULAR BASIS, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ResultsOfVerificationTxt	3	THE TRUSTEES MEET WITH ARGUS COGNITIVE, INC. MANAGEMENT ON A REGULAR BASIS, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ResultsOfVerificationTxt	4	THE TRUSTEES MEET WITH ARGUS COGNITIVE, INC. MANAGEMENT ON A REGULAR BASIS, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ResultsOfVerificationTxt	5	THE TRUSTEES MEET WITH BIOROSA TECHNOLOGIES, INC. MANAGEMENT ON A REGULAR BASIS, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ResultsOfVerificationTxt	6	THE TRUSTEES MEET WITH BIOROSA TECHNOLOGIES, INC. MANAGEMENT ON A REGULAR BASIS, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ResultsOfVerificationTxt	7	THE TRUSTEES MEET WITH BREEGI SCIENTIFIC, INC. MANAGEMENT ON A REGULAR BASIS AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ResultsOfVerificationTxt	8	THE TRUSTEES MEET WITH DECK THERAPEUTICS, INC. MANAGEMENT ON A REGULAR BASIS AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ResultsOfVerificationTxt	9	THE TRUSTEES MEET WITH INKSPACE IMAGING, INC. MANAGEMENT ON A REGULAR BASIS AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ResultsOfVerificationTxt	10	THE TRUSTEES MEET WITH MESENTECH, INC. MANAGEMENT ON A REGULAR BASIS, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ResultsOfVerificationTxt	11	THE TRUSTEES MEET WITH MOTHERS MILK IS BEST, INC. MANAGEMENT ON A REGULAR BASIS, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ResultsOfVerificationTxt	12	THE TRUSTEES MEET WITH MULBERRY BIOTHERAPEUTICS INC. MANAGEMENT ON A REGULAR BASIS, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ResultsOfVerificationTxt	13	THE TRUSTEES MEET WITH MULBERRY BIOTHERAPEUTICS INC. MANAGEMENT ON A REGULAR BASIS, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ResultsOfVerificationTxt	14	THE TRUSTEES MEET WITH NEOPENDA, PBC MANAGEMENT ON A REGULAR BASIS, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ResultsOfVerificationTxt	15	THE TRUSTEES MEET WITH NICOLETTE, INC. MANAGEMENT ON A REGULAR BASIS, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ResultsOfVerificationTxt	16	THE TRUSTEES MEET WITH NONINVASIX, INC. MANAGEMENT ON A REGULAR BASIS, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ResultsOfVerificationTxt	17	THE TRUSTEES MEET WITH NONINVASIX, INC. MANAGEMENT ON A REGULAR BASIS, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ResultsOfVerificationTxt	18	THE TRUSTEES MEET WITH NONINVASIX, INC. MANAGEMENT ON A REGULAR BASIS, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ResultsOfVerificationTxt	19	NOVONATE WAS ACQUIRED IN 2023 AND THE $150,000 WAS REPAID TO THE FOUNDATION. PRIOR TO THIS, THE TRUSTEES MET WITH NOVONATE, INC. MANAGEMENT ON A REGULAR BASIS AND REVIEWED THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ResultsOfVerificationTxt	20	THE TRUSTEES MEET WITH NURTURE GENOMICS MANAGEMENT ON A REGULAR BASIS, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ResultsOfVerificationTxt	21	THE TRUSTEES MEET WITH PLAKOUS THERAPEUTICS MANAGEMENT ON A REGULAR BASIS, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ResultsOfVerificationTxt	22	THE TRUSTEES MEET WITH PRAPELA, LLC MANAGEMENT ON A REGULAR BASIS, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY.
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ResultsOfVerificationTxt	23	THE TRUSTEES MEET WITH PRAPELA, LLC MANAGEMENT ON A REGULAR BASIS, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY.
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ResultsOfVerificationTxt	24	THE TRUSTEES MEET WITH SMOLTAP, INC. MANAGEMENT ON A REGULAR BASIS AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ResultsOfVerificationTxt	25	THE TRUSTEES MEET WITH SMOLTAP, INC. MANAGEMENT ON A REGULAR BASIS AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ResultsOfVerificationTxt	26	THE TRUSTEES MEET WITH STINGRAY THERAPEUTICS MANAGEMENT ON A REGULAR BASIS, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY.
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/ResultsOfVerificationTxt	27	THE TRUSTEES MEET WITH THINKMD, INC. MANAGEMENT ON A REGULAR BASIS, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY.
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/AddressLine1Txt	0	C/O ARSENAL LAB SPACE 201 DEXTER
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/AddressLine1Txt	1	155 BROOKLINE STREET SUITE 005
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/AddressLine1Txt	2	DARTMOUTH REGIONAL TECHNICAL CTR 16
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/AddressLine1Txt	3	DARTMOUTH REGIONAL TECHNICAL CTR 16
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/AddressLine1Txt	4	DARTMOUTH REGIONAL TECHNICAL CTR 16
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/AddressLine1Txt	5	63 BAKER STREET
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/AddressLine1Txt	6	63 BAKER STREET
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/AddressLine1Txt	7	120 BEDFORD ROAD
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/AddressLine1Txt	8	8 HARVARD LANE
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/AddressLine1Txt	9	5635 W LAS POSITAS BLVD STE 403/404
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/AddressLine1Txt	10	1510 LAKESIDE AVENUE
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/AddressLine1Txt	11	40 WALNUT STREET SUITE 301
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/AddressLine1Txt	12	40 WALNUT STREET SUITE 301
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/AddressLine1Txt	13	1623 W FULTON ST
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/AddressLine1Txt	14	100 W BROADWAY SUITE 3000
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/AddressLine1Txt	15	1700 THE STRAND SUITE 1200
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/AddressLine1Txt	16	1700 THE STRAND SUITE 1200
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/AddressLine1Txt	17	1700 THE STRAND SUITE 1200
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/AddressLine1Txt	18	395 OYSTER POINT BLVD SUITE 501
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/AddressLine1Txt	19	CAMBRIDGE INNOVATION CTR ONE
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/AddressLine1Txt	20	755 HIGHLAND OAKS DR SUITE 103
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/AddressLine1Txt	21	2 MAIN STREET
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/AddressLine1Txt	22	2 MAIN STREET
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/AddressLine1Txt	23	150 CHESTNUT STREET SUITE C
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/AddressLine1Txt	24	150 CHESTNUT STREET SUITE C
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/AddressLine1Txt	25	2450 HOLCOMBE BLVD SUITE X
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/AddressLine1Txt	26	166 MAIN STREET
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/AddressLine2Txt	0	AVE
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/AddressLine2Txt	1	CAVENDISH CT
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/AddressLine2Txt	2	CAVENDISH CT
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/AddressLine2Txt	3	CAVENDISH CT
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/AddressLine2Txt	4	BROADWAY KENDALL SQUARE
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/CityNm	0	WATERTOWN
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/CityNm	1	CAMBRIDGE
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/CityNm	2	LEBANON
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/CityNm	3	LEBANON
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/CityNm	4	LEBANON
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/CityNm	5	BELMONT
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/CityNm	6	BELMONT
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/CityNm	7	WOBURN
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/CityNm	8	HASTINGS ON HUDSON
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/CityNm	9	PLEASANTON
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/CityNm	10	FORT COLLINS
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/CityNm	11	WELLESLEY
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/CityNm	12	WELLESLEY
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/CityNm	13	CHICAGO
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/CityNm	14	LONG BEACH
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/CityNm	15	GALVESTON
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/CityNm	16	GALVESTON
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/CityNm	17	GALVESTON
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/CityNm	18	SOUTH SAN FRANCISCO
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/CityNm	19	CAMBRIDGE
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/CityNm	20	WINSTONSALEM
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/CityNm	21	BIDDEFORD
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/CityNm	22	BIDDEFORD
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/CityNm	23	PROVIDENCE
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/CityNm	24	PROVIDENCE
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/CityNm	25	HOUSTON
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/CityNm	26	BURLINGTON
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/StateAbbreviationCd	0	MA
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/StateAbbreviationCd	1	MA
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/StateAbbreviationCd	2	NH
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/StateAbbreviationCd	3	NH
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/StateAbbreviationCd	4	NH
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/StateAbbreviationCd	5	MA
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/StateAbbreviationCd	6	MA
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/StateAbbreviationCd	7	MA
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/StateAbbreviationCd	8	NY
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/StateAbbreviationCd	9	CA
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/StateAbbreviationCd	10	CO
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/StateAbbreviationCd	11	MA
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/StateAbbreviationCd	12	MA
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/StateAbbreviationCd	13	IL
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/StateAbbreviationCd	14	CA
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/StateAbbreviationCd	15	TX
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/StateAbbreviationCd	16	TX
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/StateAbbreviationCd	17	TX
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/StateAbbreviationCd	18	CA
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/StateAbbreviationCd	19	MA
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/StateAbbreviationCd	20	NC
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/StateAbbreviationCd	21	ME
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/StateAbbreviationCd	22	ME
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/StateAbbreviationCd	23	RI
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/StateAbbreviationCd	24	RI
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/StateAbbreviationCd	25	TX
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/StateAbbreviationCd	26	VT
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/ZIPCd	0	02472
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/ZIPCd	1	02139
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/ZIPCd	2	03766
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/ZIPCd	3	03766
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/ZIPCd	4	03766
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/ZIPCd	5	02478
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/ZIPCd	6	02478
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/ZIPCd	7	01801
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/ZIPCd	8	10706
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/ZIPCd	9	94588
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/ZIPCd	10	80521
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/ZIPCd	11	02481
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/ZIPCd	12	02481
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/ZIPCd	13	60612
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/ZIPCd	14	90802
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/ZIPCd	15	77555
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/ZIPCd	16	77555
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/ZIPCd	17	77555
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/ZIPCd	18	94080
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/ZIPCd	19	02142
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/ZIPCd	20	27103
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/ZIPCd	21	04005
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/ZIPCd	22	04005
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/ZIPCd	23	02903
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/ZIPCd	24	02903
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/ZIPCd	25	77021
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/USAddress/ZIPCd	26	05401
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/VerificationDt	0	2017-12-15
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/VerificationDt	1	2023-07-21
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/VerificationDt	2	2023-08-23
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/VerificationDt	3	2024-09-13
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/VerificationDt	4	2025-09-04
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/VerificationDt	5	2021-07-16
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/VerificationDt	6	2023-08-14
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/VerificationDt	7	2021-08-02
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/VerificationDt	8	2023-05-02
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/VerificationDt	9	2024-08-12
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/VerificationDt	10	2022-08-26
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/VerificationDt	11	2025-05-23
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/VerificationDt	12	2025-06-19
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/VerificationDt	13	2025-06-19
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/VerificationDt	14	2025-09-08
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/VerificationDt	15	2024-06-17
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/VerificationDt	16	2017-12-15
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/VerificationDt	17	2017-12-15
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/VerificationDt	18	2017-12-15
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/VerificationDt	19	2023-07-27
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/VerificationDt	20	2025-08-12
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/VerificationDt	21	2024-02-02
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/VerificationDt	22	2020-09-10
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/VerificationDt	23	2025-09-04
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/VerificationDt	24	2023-05-30
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/VerificationDt	25	2025-05-28
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/VerificationDt	26	2021-05-18
ExpenditureResponsibilityStmt/ExpenditureResponsibilityGrp/VerificationDt	27	2019-02-11
InvestmentsCorpBondsSchedule/InvestmentsCorporateBondsGrp/BondNm	0	FIXED INCOME
InvestmentsCorpBondsSchedule/InvestmentsCorporateBondsGrp/EOYBookValueAmt	0	17658588
InvestmentsCorpBondsSchedule/InvestmentsCorporateBondsGrp/EOYFMVAmt	0	17658588
InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt	0	34981743
InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYBookValueAmt	1	12360960
InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt	0	34981743
InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/EOYFMVAmt	1	12360960
InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/StockNm	0	DOMESTIC EQUITIES
InvestmentsCorpStockSchedule/InvestmentsCorporateStockGrp/StockNm	1	FOREIGN SECURITIES
InvestmentsOtherSchedule2/InvestmentsOtherGrp/BookValueAmt	0	6061378
InvestmentsOtherSchedule2/InvestmentsOtherGrp/BookValueAmt	1	17615779
InvestmentsOtherSchedule2/InvestmentsOtherGrp/CategoryOrItemTxt	0	REAL ESTATE
InvestmentsOtherSchedule2/InvestmentsOtherGrp/CategoryOrItemTxt	1	ALTERNATIVE INVESTMENTS
InvestmentsOtherSchedule2/InvestmentsOtherGrp/EOYFMVAmt	0	6061378
InvestmentsOtherSchedule2/InvestmentsOtherGrp/EOYFMVAmt	1	17615779
InvestmentsOtherSchedule2/InvestmentsOtherGrp/ListedAtCostOrFMVCd	0	FMV
InvestmentsOtherSchedule2/InvestmentsOtherGrp/ListedAtCostOrFMVCd	1	FMV
IRS990PF/AddressChangeInd	0	X
IRS990PF/AnalysisIncomeProducingActyGrp/DividendsAndInterestFromSecDtl/ExclusionAmt	0	2066610
IRS990PF/AnalysisIncomeProducingActyGrp/DividendsAndInterestFromSecDtl/ExclusionCd	0	14
IRS990PF/AnalysisIncomeProducingActyGrp/GainSalesAstOthThanInvntryGrp/ExclusionAmt	0	4246783
IRS990PF/AnalysisIncomeProducingActyGrp/GainSalesAstOthThanInvntryGrp/ExclusionCd	0	18